Epidermal growth factor (EGF) stands as one of the earliest identified single-chain peptides recognized for its ability to stimulate cell growth, playing a pivotal role in wound healing and maintaining tissue homeostasis by regulating cell survival, growth, motility and differentiation (6). In instances of corneal epithelial cell damage resulting from trauma, surgery or infection, EGF facilitates the migration and proliferation of corneal epithelial cells through the activation of its receptor EGFR/ErbB and subsequent binding. Consequently, this process promotes the effective repair of corneal epithelial injuries (7, 8). During the initial phases of corneal epithelial damage healing, EGFR1/ErbB1 tyrosine kinase instigates cellular signaling, activating downstream effectors such as the type III phosphoinositide 3-kinase (PI3K)—protein kinase B (Akt) axis and extracellular signal-regulated kinase (ERK). This orchestrated activation contributes significantly to the overall repair mechanism of corneal epithelial injuries (9). Furthermore, substance P also emerges as a noteworthy contributor to corneal epithelial injury repair, operating through the activation of EGFR and downstream signaling molecules, such as Akt (10). Abnormal activation of the EGFR-PI3K-AKT and ERK signaling pathways may result in increased cell apoptosis, decreased cell proliferation and delayed wound closure (11). The EGFR signaling pathway can further activate nuclear factor kappa-B (NF-κB) and histone deacetylase 6 (HDAC6). NF-κB, in turn, activates the transcription inhibitor CCCTC binding factor (CTCF) while downregulating the paired box gene 6 (PAX6), mediating the migration and proliferation of corneal epithelial cells. Simultaneously, HDAC6 promotes the migration of corneal epithelial cells and contributes to injury repair (12, 13).

There are four EGF receptors, with EGFR1 showing relatively high expression in corneal epithelial cells and demonstrating a reparative effect on the cornea during epithelial injury (14). EGFR2/ErbB2 and EGFR3/ErbB3 have also been confirmed to be expressed in the corneal epithelium, sharing a distribution pattern similar to EGFR1. Among them, the EGFR2/ErbB2 receptor enhances the corneal epithelial wound healing process by activating the ERK and PI3K signaling pathways (15). While the role of EGFR3/ErbB3 has not been fully elucidated, the existence of specific antibody inhibitors for EGFR3/ErbB3 has been confirmed. Utilizing these inhibitors and genetic techniques, studies have demonstrated that EGFR3/ErbB3 signaling can assist in the migration of corneal epithelial cells (16, 17). It’s worth noting that EGFR4/ErbB4 is not expressed in the corneal epithelium (18).

Presently, seven EGFR ligands have been identified. In addition to EGF, six other endogenous ligands capable of binding to EGFR have been recognized, including heparin-binding EGF-like growth factor (HB-EGF), transforming growth factor-α (TGF-α), betacellulin (BTC), epiregulin, amphiregulin, and epigen. HB-EGF, integral in promoting growth and development, plays a crucial role, as evidenced by the fact that knockout mice perish shortly after birth (19). Functioning as a soluble transmembrane protein, HB-EGF binds to an additional domain of negatively charged polysaccharides, thereby enhancing in vitro cell adhesion and promoting corneal epithelial injury repair (20). A notable discovery in the study indicates that HB-EGF exhibits prolonged cell attachment compared to EGF, resulting in a sustained impact on wound healing following brief therapy (21). TGF-α, a member of the epidermal growth factor family, is produced by both epidermal cells and macrophages. It plays a crucial role in the repair of corneal epithelial injuries by initiating multiple signaling cascade reactions upon binding with the EGFR (18, 22). The bidirectional interaction facilitated by TGF-α between corneal epithelial cells and mesenchymal cells assumes a pivotal morphological role in both corneal development and tissue repair. Any disruption in this intricate interplay can result in ocular lesions. Notably, TGF-α knockout mice exhibit significant ocular abnormalities, characterized by corneal epithelial thinning, inflammation, and edema (23, 24). TGF-α also promotes the proliferation of corneal epithelial and stromal cells (25). Additionally, TGF-α stimulates EGFR, facilitating the internalization and recycling of ligand-receptor complexes (22). Conversely, overexpression of TGF-α has been observed to induce corneal damage by activating EGFR in both corneal epithelium and stroma. This pathological manifestation is evident through a reduction in the number of corneal epithelial cell layers, corneal epithelial degeneration, conjunctivalization of the cornea, inhibition of the expression of the corneal pigment protein Kera, and a marked decrease in fibrocollagen types I and V collagen. Simultaneously, TGF-α overexpression can lead to corneal opacity by upregulating α-SMA and Wnt5a, while downregulating Col1a1, Col1a2, and Col5a1 (25–28). Some in vitro analysis of BTC indicates that BTC can expedite corneal epithelial injury repair and may even possess advantages over EGF in promoting corneal epithelial injury repair (18). LSCs, primarily located at the corneal-scleral junction, possess lifelong self-renewal capabilities and can produce transient amplifying cells (TACs). During corneal epithelial injury repair, TACs migrate towards the corneal center, proliferate, and differentiate into corneal epithelial cells, thereby promoting the healing of corneal epithelial wounds (29). Research has shown that treating injured mouse eyes with BTC results in significant increases in the expression of putative stem cell markers, such as DNp63α, ABCB5 and CK14. This suggests that BTC accelerates corneal LSCs proliferation and enhances mouse corneal epithelial repair by phosphorylating erk1/2 (30, 31). Despite the efficacy of various EGFR ligands in in vitro settings, in vivo wound healing is uniquely facilitated by EGF among the seven mentioned ligands. EGF also stands out as the sole ligand in human tears with an EGFR concentration closely aligned with the ligand Kd (18). Furthermore, EGFR can be reactivated through various effectors, such as phospholipase D (PLD) and extracellular ATP, to foster the migration and proliferation of cells during the wound healing process (32). Transient receptor potential (TRP) non-selective cation channels constitute a superfamily, which contains 28 different genes, and widely distributed in corneal epithelial cells and endothelial cells, its expression in the corneal epithelial layer contributes to the maintenance of corneal transparency and barrier function of the corneal epithelium. Research has shown that TRPV1 stimulation also induces increases in the proliferation and migration of corneal epithelial cells and the release of IL-6 and IL-8, and reduces the formation and of corneal neovascularization (CNV) and scar through transactivation of the EGFR. Meanwhile, TRPC4 stimulates corneal epithelial proliferation and migration by transactivation of the EGFR. TRPV in corneal epithelium can also promote homeostasis under thermal stimulation (33, 34).

While EGF holds the potential to stimulate the migration and proliferation of corneal epithelial cells, caution is warranted, as excessively increasing the intensity and duration of EGF may not yield positive effects. An experiment assessing EGF’s effectiveness has revealed potential harm from continuous daily injections in rats (35). Furthermore, injecting recombinant EGF into the cornea post-corneal epithelial cell injury can lead to CNV (36). Elevated tear EGF levels are also associated with meibomian duct hypertrophy, contributing to meibomian gland hyperplasia (37). These findings underscore the need for caution when employing exogenous EGF in treating corneal injuries. Additionally, EGFR activity is a critical determinant in maintaining corneal epithelial homeostasis and plays a pivotal role in restoring damaged corneal epithelial cells. Despite the inherent regulatory mechanisms preventing sustained EGFR signal transduction, a deeper understanding of the molecular mechanisms governing EGFR signaling holds promise for developing new methods to overcome these regulatory barriers and enhance the efficacy of EGF (Figure 2 shows the EGF signaling pathway).

Hepatocyte growth factor (HGF) is a growth factor originating from fibroblasts, predominantly produced by mesenchymal cells, and expressed in various cell types, including corneal epithelial cells, keratocytes and endothelial cells. Its mode of action is paracrine, exerting its effects on adjacent cells (38). Structurally, HGF consists of α- and β-chains and serves as a mitogen and motility factor. In the cornea, HGF plays a significant role by binding to its receptor c-met and primarily participating in the proliferation, mitosis, and morphogenesis of corneal epithelial cells (39–41).

When the corneal epithelium undergoes damage, the expression of HGF in corneal epithelial cells and keratocytes is upregulated. This upregulation activates the signal mediators phosphatidylinositol of PI3K/Akt, phosphoprotein 70 ribosomal protein S6 kinase (p70s6K), and ERK. Consequently, it controls the cell cycle, promoting cell division and proliferation of corneal epithelial cells by triggering the activity of NF-κB. Simultaneously, it reverses the anti-proliferative effect of pro-inflammatory cytokines interleukin-1β (IL-1β) and TNF-α on these cells in the inflammatory environment, mediating corneal epithelial injury repair (42–46). HGF also exhibits wound repair effects by inhibiting the inflammatory response of corneal epithelial cells. Studies have demonstrated that HGF can inhibit the activation of immune cells and the expression of inflammatory factors. It further suppresses the expression of TNF-α, monocyte chemotactic protein-1 (MCP-1), and IL-6 in the macrophage system in vitro. Additionally, it promotes the production of the anti-inflammatory cytokine IL-10 in bone marrow-derived macrophages and dendritic cells stimulated by lipopolysaccharide (LPS) (43, 47–49). Evidence supports that HGF significantly inhibits cell apoptosis, temporarily downregulates the expression of cell cycle inhibitors in corneal epithelial cells, and upregulates cyclin and cyclin-dependent kinases. It also influences tumor suppressor proteins Rb and p53, which regulate cell cycle and apoptosis. Through these mechanisms, HGF actively participates in corneal epithelial injury repair (50, 51). HGF also has the capability to penetrate through LPS-induced corneal opacity, promoting recovery, diminishing corneal fibrosis, restoring normal corneal tissue structure, and reestablishing immune quiescence after keratitis (52). In cases of diabetes-related corneal epithelial damage, HGF exhibits a reparative effect by restoring the level of c-met in the cornea of diabetic patients through downstream activation of p38 mitogen-activated protein kinase (MAPK) and the production of several putative stem cell markers. Importantly, this positive effect is observed in cultured corneas, regardless of whether gene therapy is applied to the entire corneal epithelial cells or only to the corneal edge area containing stem cells (53). Research indicates that silencing the HGF gene inhibits corneal epithelial proliferation and UVR-induced CNV. Additionally, HGF contributes to the upregulation of vascular endothelial growth factor (VEGF) and plays a role in angiogenesis regulation. These findings open up new avenues for exploring treatment strategies for CNV (54, 55).

Insulin-like growth factor (IGF) belongs to the multifunctional cell proliferation regulatory factor, representing a group of peptide substances capable of promoting growth. Its secretory cells are widely distributed in various tissues, including the liver, kidneys, heart and eyes of the human body. The IGF family comprises two peptide ligands (IGF-1 and IGF-2), three receptors, and six binding proteins, collectively maintaining tissue homeostasis by regulating metabolism and/or mitotic pathways at the level of all corneal cells (56).

IGF-1, a multifunctional cytokine with broad biological activity, holds considerable promise for applications in corneal epithelial injury repair. By binding to the insulin-like growth factor 1 receptor (IGF-1R), IGF-1 actively maintains and regulates corneal epithelial cell growth, proliferation, differentiation, maturation, migration, regeneration, and energy metabolism. It promotes corneal epithelial cell proliferation through the activation of the hybrid of IGF-1R and insulin receptor (INSR), leading to subsequent Akt phosphorylation. Additionally, IGF-1 mediates corneal epithelial cell migration through the PI3K/AKT pathway. Furthermore, IGF-1 promotes the expression of IGF receptors in corneal limbal cells, stimulating LSCs to differentiate into corneal epithelial cells (57, 58). Beyond its role in cell proliferation and migration, IGF-1 serves as a crucial neurotrophic factor facilitating the regeneration and restoration of nerves following peripheral nerve damage in the cornea (59). In combination with substance P, IGF-1 demonstrates a synergistic effect in promoting corneal epithelial injury repair. The co-application accelerates the ex vivo migration of corneal epithelial cells in the injured corneal stroma. Mediated by the interaction between substance P and tachykinin receptors, it enhances the adhesion of corneal epithelium to fibronectin (FN) and type IV collagen, thereby augmenting the protective role of the corneal epithelium through the stimulation of wound healing (60–64). The low levels of IGF-1 in tears, particularly the reduced proportion of IGF-1 and IGF binding protein 3 (IGFBP-3) in tears of diabetic patients, have been associated with decreased proliferation of corneal epithelial cells and delayed wound repair. This change inhibits the capacity of IGF-1 to induce IGF-1R or hybrid R phosphorylation (65, 66). Research has demonstrated that mRNA of adipose-derived stem cells (ADSCs) modified with IGF-1 exhibits stronger cell proliferation and migration abilities, promoting wound repair, morphological and functional recovery, corneal nerve regeneration, and maintenance of corneal homeostasis after acute alkali burns. Importantly, it can prevent the generation of CNV and corneal lymphatic vessels, highlighting the crucial role of IGF-1 in the repair of corneal epithelial injury (60). However, the application of IGF-1 protein to the cornea in the form of eye drops faces limitations, including a limited duration of effect, elevated attrition rates, and the need for repeated administration. Further research is expected to explore new carrier forms that can overcome these shortcomings and enhance the effectiveness of IGF-1 in corneal injury repair. The expression of IGF-2 and its receptors significantly increases after corneal epithelial cell injury, promoting the transformation of LSCs in the basal layer of the cornea into corneal epithelial cells and subsequently supporting corneal epithelial cell repair (67). Additionally, both IGF-1 and IGF-2 play roles in promoting the proliferation of keratocytes and collagen synthesis (68).

IGFBP primarily exists in the aqueous humor and vitreous body, exerting unique, cell- and tissue-dependent effects through interactions with the IGF family via binding (69–71). The primary function of IGFBP is to bind to IGF-1, extending its half-life in circulation and preventing IGF-1R activation induced by IGF-1 (72, 73). IGFBP-2 and IGFBP-3 play pivotal roles in corneal tissue homeostasis, particularly in regulating the growth of corneal epithelial cells and the localization of intracellular receptors (74, 75). The mutual regulation between IGFBP-3 and IGF-1R maintains corneal epithelial homeostasis. Previous studies have shown that IGFBP-3 is essential for inducing the transport of IGF-1R, and the absence of IGF-1R will downregulate IGFBP-3 in turn (76). During conditions such as hypoxia and hyperglycemia, the secretion of IGFBP-3 increases. For instance, the level of IGFBP-3 in the tears of diabetic patients rises, suggesting its potential role in regulating eye homeostasis in diabetic patients and indicating therapeutic potential in ocular surface diseases associated with diabetes (66).

Moreover, IGF and insulin share a close relationship, with the former mediating the action of insulin to promote the growth of corneal epithelial cells. This suggests a potential collaborative repair effect between the two, offering a promising avenue for future research exploration (77, 78).

Neurogenic growth factor (NGF) belongs to the family of neurotrophic factors, exhibiting dual biological functions of neuronal nourishment and promoting synaptic growth (79). In the context of the cornea, signals mediated by NGF propagate through the high-affinity receptor tropomyosin receptor kinase A (TrkA) and the low-affinity non-selective transmembrane glycoprotein receptor p75NTR. When combined with NGF, TrkA activates Ras MAPK, ERK, phospholipase C-γ (PLC-γ), and PI3K. This activation includes stimulating D-type cell cycle regulatory proteins through PI3K/Akt and MAPK/ERK, subsequently promoting corneal epithelial cell cycle progression. Simultaneously, p75NTR activates the c-Jun kinase and NF-kB signaling pathway, exhibiting a protective effect on corneal epithelial cells by inhibiting the inflammatory signaling pathway of NF-kB (80–82).

Research has demonstrated that NGF participates in the repair process of corneal epithelial and stromal damage by upregulating matrix metalloproteinase-9 (MMP-9) and cleaving integrins β4 to stimulate the migration of corneal epithelial cells, promotes the differentiation of keratocytes into myofibroblasts, and reduces the formation of corneal haze (83–85). Moreover, NGF induces the differentiation of goblet cells and the production of mucin through receptors expressed in the lacrimal gland and neural reflexes, thereby contributing to the maintenance of corneal epithelial function (86). In addition to its role in cellular functions, NGF regulates immune function through Toll-like receptors (TLRs) in corneal physiology and pathology, playing a crucial role in maintaining corneal homeostasis both in vivo and in vitro settings (87). NGF has also been identified as a key promoter for the proliferation of LSCs, the formation of colonies in LSCs, and the maintenance of the LSC phenotype (79). For patients with corneal ulcers, local application of NGF eye drops has been shown to improve the speed of corneal epithelial repair and the sensitivity of the cornea. In cases of herpes simplex keratitis (HSK), endogenous NGF, akin to acyclovir, significantly improves the condition and inhibits recurrence. Clinical studies indicate that eye drops containing NGF can induce complete healing in HSK patients resistant to acyclovir (88, 89). Treatment with recombinant human NGF (rhNGF) has proven effective in enhancing corneal perception in patients with neurotrophic keratitis (NK) by increasing the density and number of nerve fibers in the basal layer of the corneal epithelium. It also promotes the healing of persistent corneal epithelial defects and ulcers. Furthermore, rhNGF provides lubrication and natural protection against pathogen damage to the corneal epithelium by promoting tear secretion from the lacrimal gland. RhNGF has received approval as a primary therapeutic drug for NK (87, 88). Additionally, NGF exhibits the ability to inhibit oxidative damage caused by hyperosmotic stress or high glucose levels. This finding suggests its potential therapeutic effect on conditions such as dry eye syndrome and diabetic keratopathy (DK) (90, 91).

TGF is a protein composed of amino acids in the cytoplasm, belonging to the family of peptide growth factors. It includes two main types: TGF-α and TGF-β (92). TGF-α has been described in the EGF section. TGF-β is a multifunctional growth factor, further divided into three subtypes: TGF-β1, TGF-β2 and TGF-β3. All three subtypes and their receptors are expressed in corneal epithelium and keratocytes (93). TGF-β assumes a pivotal role in orchestrating and coordinating the response to corneal injury repair, exerting influence over various facets such as the proliferation, motility, and differentiation of corneal epithelial cells. Moreover, TGF-β modulates the activity and apoptosis of keratocytes, as well as the development of myofibroblasts (94). By stimulating the migration of corneal epithelial cells through integrin β1, TGF-β enhances the fluidity of these cells (95). Notably, the conditional ablation of its type II receptor has been found to impede the repair of corneal epithelial wounds and the activation of p38 MAPK, thereby hindering the migration of corneal epithelial cells (96). Furthermore, TGF-β2 has been substantiated to expedite the repair of corneal epithelial wounds in rabbits, augmenting barrier integrity by promoting cell adhesion to substrates and enhancing the functionality of corneal endothelial cells (CECs) (97). Tgfbr-2 also plays a crucial role in maintaining corneal stromal homeostasis, as studies have demonstrated that Tgfbr-2 knockout mice display significant corneal thinning and a potential for corneal ectasia (98). TGF-β3 exhibits the capability to mitigate interstitial scars induced by the activity of TGF-β1 and TGF-β2. Moreover, it demonstrates potential therapeutic effects in addressing corneal and skin wounds in diabetic patients, acting through the PI3K-Akt and SMAD signaling pathways, along with their target genes (99). Additionally, if the Bowman layer is damaged, corneal cells are highly susceptible to exposure to TGF-β. In such cases, TGF-β promotes damage repair through various mechanisms (100). Despite its essential role in corneal epithelial injury repair, TGF-β also has negative effects on the cornea. For instance, it can promote the aging of corneal epithelial cells through the NF-κB signaling pathway. This aging process can be alleviated by inhibiting the NF-κB signaling pathway (101). TGF-β is implicated in the pathogenesis of various eye diseases, including pterygium, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and graft-versus-host disease (GVHD). Elevated levels of TGF-β are observed in the corneas of individuals with these diseases (102). Additionally, TGF-β regulates the transformation of corneal epithelial cells and corneal fibroblasts into myofibroblasts, and the high expression of α-SMA and F-actin in myofibroblasts can lead to the loss of corneal transparency and corresponding corneal haze (103). Moreover, TGF-β1 and TGF-β2 can prevent corneal epithelial cells from proliferating in vitro (104).

Platelet-derived growth factor (PDGF), secreted by epithelial cells, endothelial cells and inflammatory cells, serves as a potent mitogenic factor, existing in diverse isoforms, namely PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD, and PDGF-AB (105). Featuring both α and β types of receptors, PDGF exerts its cellular effects by inducing the complex formation of α-tyrosine kinase receptors and β-tyrosine kinase receptors. This induction, in turn, triggers processes such as cell growth, chemotaxis, actin recombination and protection against apoptosis. Analogous to TGF-β, PDGF assumes a pivotal role in regulating and coordinating the response to corneal wound repair. It influences the proliferation, motility and differentiation of corneal epithelial cells, while also modulating the activity and apoptosis of keratocytes and contributing to the development of myofibroblasts (94). Corneal epithelial cells express PDGF AA, PDGF BB and PDGF AB, which regulate the migration and proliferation of keratocytes. In the presence of FN, these isoforms can enhance the migration of corneal epithelial cells (106–108). Research indicates that PDGF-AB and PDGF-BB promote the migration of corneal fibroblasts in vitro, leading to an increase in the concentration of cytosolic free Ca²⁺. PDGF-BB also significantly stimulates DNA synthesis in bovine corneal endothelial cells (BCEC) and human corneal fibroblasts (HCF) in a dose-dependent manner (108–110). Moreover, under high fibroblast density, PDGF isomers act as mitogens for interstitial fibroblasts during wound healing, conversely, at low cell density, PDGF-AA and PDGF-AB can prevent cell loss during the corneal homeostasis process (111). The secretion of PDGF is activated during corneal trauma, infection, or inflammation, providing significant stimulation for tissue repair. However, hyperstimulation can have negative effects. For instance, PDGF-α hyperstimulation can promote the proliferation and migration of lens epithelial cells, leading to epithelial-mesenchymal transition (EMT) (112, 113).

Fibroblast growth factor (FGF) is secreted by the hypothalamus and pituitary gland, serving as a broad-spectrum mitogen, currently, at least 23 FGF families have been identified, stimulating or maintaining specific cellular functions required for tissue metabolism, homeostasis and development through signaling axes mediated by their receptors (114). Corneal epithelial changes, accompanied by decreased vision and dry eye symptoms, have been observed after treatment with inhibitors of the FGF receptor (FGFR), indirectly indicating FGF’s involvement in corneal epithelial homeostasis (115). Basic FGF (b-FGF/FGF2), approved for the treatment of corneal damage, accelerates the repair of corneal epithelial cell damage and reduces keratitis by promoting the proliferation, differentiation and migration of corneal epithelial cells (116, 117). In experiments involving FGFR2 knockout mice, observations reveal localized central corneal thinning, along with the loss of collagen fibers and apoptosis of keratocytes (118). In addition, the signal transduction of FGFR2b promotes corneal epithelial injury repair, studies have found that FGFR2b knockout mice exhibit reduced proliferation of corneal epithelial cells, as well as loss of lacrimal gland and meibomian gland. FGFR2b is also necessary for the development of submandibular glands (119). FGF-10 plays a crucial role in the development of the cornea, morphogenesis and growth of the lens and induction and branching of the lacrimal gland and meibomian gland. Research has shown that FGF-10 is essential for the development of lacrimal glands in humans and mice (120, 121). FGF-10 can upregulate the expression of mucin in conjunctival epithelial cells, protecting the ocular surface in a dry eye model of rabbits and controlling the migration of epithelial cells during the process of embryonic eyelid closure (122, 123). Additionally, FGF-10 is associated with adult tissue homeostasis and the function of stem cells (124). In an experimental study of DK, it has been found that rhFGF-21 can improve the vitality and migration of human corneal epithelial cells, promote the healing of corneal wounds and the production of tears, and improve corneal edema. RhFGF-21 significantly reduces the expression of pro-inflammatory cytokines such as TNF-α and MMPs in corneal epithelial cells, while increasing the level of anti-inflammatory molecules IL-10 and SOD-1. RhFGF-21 also inhibits excessive production of reactive oxygen species (ROS) and alleviates oxidative stress induced by hyperglycemia in corneal epithelial cells. Therefore, the application of drugs containing FGF-21 may be a potential treatment method for DK (125, 126).

Keratinocyte growth factor (KGF) belongs to the FGF family, officially known as FGF-7. It is produced by mesenchymal cells and acts on adjacent cells in a paracrine manner. KGF promotes the repair of corneal epithelial wounds through the signaling cascade of MAPK and PI3K/p70 S6 in corneal epithelial cells. It also inhibits the destruction of the barrier function caused by hypoxia in corneal epithelial cells by activating ERK (46, 127, 128). In vitro experiments have shown that KGF can protect cells from apoptosis for an extended period, with the final percentage of apoptosis in cells treated with KGF being only 10% (129). Similar to HGF, KGF has the capacity to inhibit UVR-induced corneal epithelial proliferation. Through gene silencing, it downregulates the expression of VEGF and its receptors, consequently mitigating CNV (48, 49). Additionally, KGF-2 exhibits certain effects in re-epithelialization, accelerating migration, reducing scar formation and edema. It is considered superior to b-FGF and holds potential as a new drug for treating corneal injuries (116). KGF also can promote the migration of LSCs, thereby promoting the repair of corneal epithelial damage (36).

Opioid growth factor (OGF) is an endogenous peptide found together with its receptor OGFr in or on the basal layer of many species’ corneas, when combined, OGF regulates DNA synthesis in corneal epithelial cells and influences cell migration (130). Experimental evidence suggests that OGF inhibits cell overgrowth by upregulating cyclin-dependent inhibitory kinases p16 and p21, contributing to the maintenance of corneal epithelial homeostasis (131). Studies conducted on patients and rats with diabetes have indicated elevated levels of OGF and OGFr in serum and corneal epithelium. This elevation has been associated with ocular surface complications, including dry eyes, abnormal sensitivity of the corneal surface, and delayed corneal epithelial repair. In rats, an OGF-OGFr axis is present in the corneal limbus, and its dysregulation in hyperglycemia impacts the morphology of the corneal limbus, exacerbating diabetes-related complications on the corneal surface. Local application of the opioid antagonist naltrexone (NTX) has demonstrated improvement in this situation (132, 133). NTX disrupts the OGF-OGFr interaction, resulting in increased DNA synthesis in epithelial cells of the peripheral cornea and limbus corneae, as well as the proliferation of fibroblast cells. The latter plays a crucial role in corneal wound healing (134, 135). Additionally, the application of NTX significantly promotes corneal re-epithelialization and increases tear production (136–138). In summary, the use of eye drops containing opioid antagonists, such as NTX, holds promise as a novel therapy for treating wound repair disorders of the corneal epithelium.

VEGF, recognized as a highly specific mitogen promoting endothelial cell growth, is also referred to as vascular permeability factor (VPF) due to its ability to significantly enhance vascular permeability (139). The VEGF family comprises seven subtypes: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor (PLGF). Additionally, there are three receptors, VEGFR-1, VEGFR-2, and VEGFR-3. Among these, VEGF-A stands out for its profound ability to promote angiogenesis and is the most prevalent subtype in the eyes (140). The VEGF family and its receptors are expressed in the corneal epithelium (4). Under normal circumstances, a delicate balance is maintained between ocular angiogenic factors and anti-angiogenic factors to prevent pathological CNV production. However, factors such as wearing contact lenses, inflammation, and infection can disrupt this balance and lead to CNV (141). Research has highlighted the crucial role of VEGF in the pathogenesis of CNV, making the use of anti-VEGF drugs a feasible therapeutic approach (142, 143). Additionally, VEGF is implicated in non-angiogenic functions, such as neuroprotection and serving as a nutritional factor for corneal nerves (144). VEGF also plays a role in wound repair; studies have shown that VEGF accelerates corneal epithelial wound healing by stimulating corneal nerve regeneration (145). VEGF may be linked to the pathogenesis of pterygium, with higher expression detected in pterygium compared to normal tissue (146). Pigment epithelial-derived factors (PEDFs) are closely related to VEGF, sharing anti-angiogenic functions and a protective role for corneal nerves (147). Both factors exhibit synergistic therapeutic effects in certain diseases. However, in pterygium, a decrease in PEDF expression has been observed (146). Moreover, PEDF has been found to promote the self-renewal and migration of LSCs, thereby facilitating corneal epithelial repair (148). (The expression of growth factors in the corneal epithelium is depicted in Figure 3, and the biological effects of corneal epithelial growth factor receptors are summarized in Table 1).